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Summary
Dyskeratosis Congenita (DKC) is a systemic disorder caused by mutations resulting
in impaired telomere maintenance. Clinical features include bone marrow failure
and an increased risk of developing hematological malignancies. There are conflict-
ing data whether androgen derivatives (AD) can elongate telomeres in vivo and
whether AD treatment enhances the risk of gaining myelodysplastic syndrome-re-
lated mutations. Seven TERC or TERT-mutated DKC patients underwent AD treat-
ment. All patients revealed hematological response. Telomere length of lymphocytes
and granulocytes increased significantly and no MDS-related mutations were
detected. Pending longer follow-up, treatment with AD seems to represent an effi-
cient and safe therapy for DKC patients.
Keywords: telomere, androgens, dyskeratosis congenita, bone marrow fail-
ure, MDS.
Key Points
 Androgen derivatives significantly improve blood counts
and elongate telomeres in patients with dyskeratosis
congenita with TERT or TERC mutations in vivo.
 No myelodysplastic syndrome-related somatic mutations
were observed during telomerase activation with andro-
gen derivatives.
Classical dyskeratosis congenita (DKC) is a hereditary disorder
mainly characterized by mucocutaneous features and bone
marrow failure.1 In adults, so-called ‘cryptic’ DKC manifests
itself mostly with progressive bone marrow failure (occurring
in >90% of the cases) and pulmonary fibrosis or secondary
cancers; primarily affecting tissues with high cellular turnover.
DKC is caused by mutations suppressing proper telomere
maintenance and leading to premature telomere shortening.1
Most mutations affect subunits of telomerase itself, namely
telomerase reverse transcriptase (TERT) or the telomerase
RNA component (TERC). However, various other mutations
in genes coding for helicases, e.g. regulator of telomere elonga-
tion helicase 1 (RTEL1), or the ribosomal core component H/
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ACA ribonucleoprotein complex subunit DKC1 (DKC1) have
been described.1 Flow-FISH as the method of choice is used
for assessment of telomere length (TL) to screen for and diag-
nose DKC.2 Preclinical in vitro3 and in vivo4 studies as well as
clinical case reports providing proof-of-principle5 paved the
way for systematic clinical trials eventually confirming that
androgen derivatives (AD) such as danazol or oxymetholone
can not only improve blood counts and reduce transfusion fre-
quency but in fact increase telomere length in patients with
DKC.5,6 AD are thought to elongate telomeres by increasing
the expression of telomerase thereby at least partially reversing
the mutation-related haploinsufficiency of the telomerase
complex.3,4 However, whether consistent and stable telomere
elongation can be maintained long-term in vivo is still
debated.7 Unfortunately, patients with DKC have been shown
to harbor an increased risk of developing solid tumors as well
as myeloid neoplasms such as acute myeloid leukemia (AML)
or myelodysplastic syndrome (MDS).8 Recent studies favor the
hypothesis that malignant transformation is mostly mediated
by chromosomal instability due to critically short telomeres
and not primarily via clonal hematopoiesis of indeterminate
potential (CHIP) and eventual selection for MDS-related
somatic mutations.9 Hence, the question arises whether
increased telomerase activity mediated by AD further increases
the risk for CHIP development in DKC patients treated with
AD. Here, we aimed to sequentially investigate the effect of AD
both on TL as well as on MDS-related somatic mutations in
patients with adult-onset (cryptic) DKC.
Methods and patients
Seven patients with molecularly confirmed DKC were enrolled
in our analysis (see Table I). All TL assessments of peripheral
blood granulocytes and lymphocytes were carried out by Flow-
FISH, the results are given in kilobases (kb) as previously
described.2 Before initiation of AD treatment, telomere attri-
tion below the 1st percentile of normal controls was confirmed
in all cases in lymphocytes and in 6 out of 7 in the granulo-
cytes. Six patients received danazol treatment while patient #5
was treated with low dose oxymetholone (see Table I). All
patients were treated with AD for the first time and none had
concomitant medication with growth factors. Patients were at
a median age of 40 years (range: 21–53 years) at start of ther-
apy. Median follow-up during treatment was 14 months
(range: 3–29 months, Table I). Blood cell counts were assessed
by the local treating physicians. TL and next-generation
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The population analyzed comprises adult patients screened for late onset of hereditary telomeropathies. Parts of the genetic characteristics of the
patients population are described in Ventura Ferreira et al.2,13 abs., absolute; PR, partial remission; CR, complete remission; ILD, interstitial lung
disease; HNSCC, Head and neck squamous cell cancer; BMF, bone marrow failure. All DKC-confirming mutations were heterozygous. Transcript
used for variant annotation: *TERC: NR_001566; **TERT: NM_198253; †no concomitant treatment with growth factor (e.g granulocyte stimulat-
ing factor or thrombopoietin receptor agonists).
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sequencing (NGS) analysis of patients were assessed before AD
treatment and at the last time point available during treatment.
Response assessment was carried out as described previously
(for further detail see Methods S1).
Results and discussion
In all seven patients with mutations in the telomerase genes
TERC and TERT and short TL at baseline, mean TL
Fig 1. (A) Telomere length in lymphocytes
(upper panel) and granulocytes (lower panel)
at baseline and during androgen treatment. (B)
Individual course of telomere length during
treatment in case #7. (C) Improvement of
hematological parameters during androgen
treatment. The grey horizontal arrow repre-
sents the duration of the androgen treatment.
One arrow indicates partial response (⇩), two
arrows indicate complete response (⇩⇩). plate-
lets/thrombopoiesis are shown in blank arrows
(⇩), hemoglobin/erythropoiesis in red shaded
arrows ( ), neutrophils/granulopoiesis in green
filled arrows ( ). [Colour figure can be viewed
at wileyonlinelibrary.com]
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increased significantly during AD treatment (Fig 1A). Lym-
phocyte TL increased significantly from a mean
445  037 kb at baseline to 528  068 kb (P = 0003,
Figure S2A). TL in the granulocyte subpopulation increased
from 472  040 kb before treatment start to
605  049 kb under treatment (P = 0003, Figure S2B).
For patient #7, continuous TL measurement during treat-
ment was available. TL increased quickly following treatment
initiation with AD followed by a subsequent stabilization
under continued treatment (Fig 1B). For all patients, median
increase in TL per month for lymphocytes and granulocytes
was 011 kb (0019–0223 kb) and 0153 kb (0019–
0513 kb).
All seven patients showed a hematological response during
treatment with AD in at least one hematopoietic myeloid lin-
eage (Figure S1). Peripheral blood counts revealed a signifi-
cant increase in granulocyte counts from a mean of 14/
µl  06 to 42/µl  2.1 (P = 0049, Figure S1A), in hemo-
globin levels from a mean of 92 g/dl  23 to 112 g/
dl  29 (P = 0027, Figure S1B), and in platelet counts
increasing from a mean of 45/nl  45 before treatment to
69/nl  54 (P = 0036, Figure S1C) during AD treatment.
These data are in line with previous observations of patients
harboring TERC or TERT mutations who clinically benefitted
from AD derivatives.6
Here, in line with previous studies,5,6 we were able to con-
firm that both blood counts and TL improve under treat-
ment with AD in patients with DKC. However, a recent
study by Khincha et al. failed to see a significant telomere
elongation in ten DKC patients upon AD therapy after a
median treatment duration of 3 years.7 One potential expla-
nation for this discordance could reside in the fact that the
response to AD treatment might depend on the underlying
mutational profile which can be observed in different cohorts
of DKC patients. Our study includes a genetically rather
homogenous population of patients with TERC and TERT
mutations only, while Khincha et al.7 analyzed a genetically
much more heterogeneous cohort including only one TERC-
mutated patient. In vitro data have shown that AD can lead
to an increased expression of the telomerase protein TERT.3
Consequently, in patients with mutation-related haploinsuffi-
ciency of TERC or TERT, AD treatment is expected to lead
to an increase of telomerase activity resulting in telomere
elongation. In contrast, mutations of other telomerase com-
plex members can either cause substantial loss of function,
such as in DKC1-mutated patients,10 or - as in RTEL1-mu-
tated patients11 - indirectly impair telomerase activity while
the telomerase complex itself still remains functional. In both
cases, an AD-mediated increase in telomerase expression
would not necessarily result in elongated telomeres since
telomere maintenance is independent of the levels of telom-
erase activity. In line with this assumption, the TERC-mu-
tated patient within the cohort reported by Khincha et al.
did indeed experience a hematological response and mild
telomere elongation.7
Finally, our NGS analysis looking for possible MDS-re-
lated mutations did not reveal any newly evolving mutations
under AD treatment. We previously showed that MDS-
related mutations are generally infrequent in patients with
DKC.9 This clearly differs from patients with myeloid dis-
eases characterized by short telomeres but unimpaired func-
tional telomerases such as patients with acquired aplastic
anemia or elderly individuals with MDS.12-15 Nonetheless,
one major concern in regards to AD treatment of DKC
patients is that reactivation of telomerase complex could sta-
bilize genetically instable clones with short telomeres and
eventually increase the frequency of MDS-related mutations.
In conclusion, AD treatment for patients with adult-onset,
cryptic DKC represents an efficient and safe therapy for
patients harboring TERT or TERC mutations and short TL
by significantly improving peripheral blood counts with elon-
gation of telomeres. Due to the rarity and genetic heterogene-
ity of the disease, valid conclusions regarding the persistence
of the observed beneficial effects and long-term safety of AD
treatment in DKC patients pends on further investigation.
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Fig SI. Clinical parameters before and under treatment
with AD. Improvement of clinical parameters, such as granu-
locytes (A), hemoglobin (B), and platelets (C) after treatment
with AD. Statistical analysis was performed using students
paired t-test.
Fig SII. Increase of telomere length measured by flow-
FISH. The increase of telomere length in lymphocytes (A)
and in granulocytes (B) after treatment with AD measured
by flow-FISH is shown. Statistical analysis was performed
using students paired t-test.
Methods S1. Supplementary methods.
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